Serkan Aksu1,2,3, Atilla Uslu4, Pınar İşçen5, Emine Elif Tülay6, Huzeyfe Barham7, Ahmet Zihni Soyata8, Asli Demirtas-Tatlidede9, Gülsen Babacan Yıldız10, Başar Bilgiç5, Haşmet Hanağası5, Adam J Woods11, Sacit Karamürsel12, Fatma Aytül Uyar13,4. 1. Department of Physiology, Graduate School of Health Sciences, Istanbul University, Istanbul, Turkey. serkanaksu@mu.edu.tr. 2. Department of Physiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. serkanaksu@mu.edu.tr. 3. Department of Physiology, Faculty of Medicine, Muğla Sıtkı Koçman University, Muğla, Turkey. serkanaksu@mu.edu.tr. 4. Department of Physiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 5. Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 6. Department of Software Engineering, Faculty of Engineering, Muğla Sıtkı Koçman University, Muğla, Turkey. 7. Department of Psychiatry, Kırklareli Research and Training Hospital, Kırklareli, Turkey. 8. Department of Psychiatry, Ergani State Hospital, Diyarbakır, Turkey. 9. Department of Neurology, School of Medicine, Bahcesehir University, Istanbul, Turkey. 10. Private Clinic, Istanbul, Turkey. 11. Department of Clinical and Health Psychology, Center for Cognitive Aging and Memory, McKnight Brain Institute, Cognitive Aging and Memory Clinical Translational Research Program, University of Florida, Gainesville, USA. 12. Department of Physiology, School of Medicine, Koç University, Istanbul, Turkey. 13. Department of Physiology, Graduate School of Health Sciences, Istanbul University, Istanbul, Turkey.
Abstract
BACKGROUND: Parkinson's disease-mild cognitive impairment (PD-MCI) is garnering attention as a key interventional period for cognitive impairment. Currently, there are no approved treatments for PD-MCI and encouraging results of transcranial direct current stimulation (tDCS) combined with other interventions have been proposed, though the efficacy and neural mechanisms of tDCS alone have not been studied in PD-MCI yet. OBJECTIVES: The present double-blind, randomized, sham-controlled study assessed the effects of tDCS over the dorsolateral prefrontal cortex on cognitive functions via neuropsychological and electrophysiological evaluations in individuals with PD-MCI for the first time. METHOD: Twenty-six individuals with PD-MCI were administered 10 sessions of active (n = 13) or sham (n = 13) prefrontal tDCS twice a day, for 5 days. Changes were tested through a comprehensive neuropsychological battery and event-related potential recordings, which were performed before, immediately, and 1 month after the administrations. RESULTS: Neuropsychological assessment showed an improvement in delayed recall and executive functions in the active group. N1 amplitudes in response to targets in the oddball test-likely indexing attention and discriminability and NoGo N2 amplitudes in the continuous performance test-likely indexing cognitive control and conflict monitoring increased in the active group. Active stimulation elicited higher benefits 1 month after the administrations. CONCLUSION: The present findings substantiate the efficacy of tDCS on cognitive control and episodic memory, along with the neural underpinnings of cognitive control, highlighting its potential for therapeutic utility in PD-MCI. TRIAL REGISTRATION: NCT 04,171,804. Date of registration: 21/11/2019.
BACKGROUND: Parkinson's disease-mild cognitive impairment (PD-MCI) is garnering attention as a key interventional period for cognitive impairment. Currently, there are no approved treatments for PD-MCI and encouraging results of transcranial direct current stimulation (tDCS) combined with other interventions have been proposed, though the efficacy and neural mechanisms of tDCS alone have not been studied in PD-MCI yet. OBJECTIVES: The present double-blind, randomized, sham-controlled study assessed the effects of tDCS over the dorsolateral prefrontal cortex on cognitive functions via neuropsychological and electrophysiological evaluations in individuals with PD-MCI for the first time. METHOD: Twenty-six individuals with PD-MCI were administered 10 sessions of active (n = 13) or sham (n = 13) prefrontal tDCS twice a day, for 5 days. Changes were tested through a comprehensive neuropsychological battery and event-related potential recordings, which were performed before, immediately, and 1 month after the administrations. RESULTS: Neuropsychological assessment showed an improvement in delayed recall and executive functions in the active group. N1 amplitudes in response to targets in the oddball test-likely indexing attention and discriminability and NoGo N2 amplitudes in the continuous performance test-likely indexing cognitive control and conflict monitoring increased in the active group. Active stimulation elicited higher benefits 1 month after the administrations. CONCLUSION: The present findings substantiate the efficacy of tDCS on cognitive control and episodic memory, along with the neural underpinnings of cognitive control, highlighting its potential for therapeutic utility in PD-MCI. TRIAL REGISTRATION: NCT 04,171,804. Date of registration: 21/11/2019.
Authors: Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre Journal: Mov Disord Date: 2012-01-24 Impact factor: 10.338
Authors: Rosa Manenti; Maria Sofia Cotelli; Chiara Cobelli; Elena Gobbi; Michela Brambilla; Danila Rusich; Antonella Alberici; Alessandro Padovani; Barbara Borroni; Maria Cotelli Journal: Brain Stimul Date: 2018-07-18 Impact factor: 8.955